Panic Disorder with Glutamic Acid Decarboxylase Abnormalities
Find information on Panic Disorder with Glutamic Acid Decarboxylase Abnormalities including clinical documentation, medical coding, diagnostic criteria, GAD antibodies, and treatment options. Learn about the connection between GABAergic dysfunction and panic disorder symptoms, plus relevant healthcare resources for patients and medical professionals. Explore the role of glutamic acid decarboxylase in neuropsychiatric disorders and its impact on anxiety and panic attacks. This resource provides insights into accurate diagnosis coding and effective clinical management strategies for Panic Disorder related to GAD abnormalities.
Anxiety disorder marked by sudden, recurrent panic attacks with intense fear.
Palpitations, sweating, trembling, shortness of breath, chest pain, dizziness, fear of losing control.
Primary care, psychiatry, therapy, emergency room, telehealth consultations.
ICD-10 Code Families
Complete code families applicable to F41.0
When to use each related code
| Description | When to use |
|---|---|
| Panic Disorder | Recurrent unexpected panic attacks with persistent worry about future attacks or behavioral change. |
| GAD with GADAbnormalities | Generalized anxiety disorder with documented glutamic acid decarboxylase antibody abnormalities, consider if stiff person syndrome features present. |
| Stiff Person Syndrome | Progressive muscle stiffness, rigidity, spasms, and heightened sensitivity to stimuli, often with GADAbnormalities. |
Best-practice checklist
- ✓Panic disorder diagnosis (DSM-5 300.01)
- ✓GAD antibody test results documented
- ✓Symptoms frequency, intensity, duration
- ✓Impairment in daily life specified
- ✓Differential diagnosis considerations noted
Common pitfalls to avoid
Lack of clear documentation linking panic disorder to GAD abnormality may lead to coding errors and claim denials. ICD-10-CM requires specific documentation.
Coding panic disorder without specifying the presence of GAD abnormalities can result in undercoding and loss of revenue. CDI review is crucial.
Insufficient documentation supporting the medical necessity of tests for GAD abnormalities with panic disorder can cause claim denials. Clear linkage is key.
Best-practice tips
- 01Accurate ICD-10-CM coding: F41.0, GAD with documented GAD antibody testing.
- 02CDI: Detail panic symptoms & GAD antibody results in clinical notes.
- 03Compliance: Ensure GAD antibody tests are medically necessary per payer guidelines.
- 04Differential diagnosis: Rule out other anxiety disorders, consider comorbid conditions.
- 05Treatment plan: Note GAD-specific treatments like GABAergic medications, psychotherapy.
Step-by-step checklist
- 1
1. Unexpected panic attacks documented (ICD-10 F41.0)
- 2
2. GAD antibody test ordered and reviewed
- 3
3. Rule out other anxiety disorders (DDx documentation)
- 4
4. Assess for neurological symptoms (patient safety)
- 5
5. Consider Stiff Person Syndrome if GAD positive
Ready-to-paste narrative
Patient presents with recurrent unexpected panic attacks, meeting DSM-5 criteria for Panic Disorder. Symptoms include palpitations, sweating, trembling, shortness of breath, feelings of choking, chest pain, nausea, dizziness, derealization, fear of losing control, and fear of dying. These episodes are not substance-induced or attributable to another medical condition. The patient reports significant anticipatory anxiety and maladaptive behavioral changes related to the attacks, such as avoidance of situations where previous attacks have occurred. Differential diagnoses considered include generalized anxiety disorder, agoraphobia, specific phobias, and other anxiety disorders. Clinical assessment suggests a possible link to glutamic acid decarboxylase (GAD) abnormalities, supported by family history of autoimmune conditions and patient-reported symptoms suggestive of possible GABAergic dysfunction, such as heightened anxiety sensitivity, insomnia, and muscle tension. Further investigation, possibly including GAD antibody testing, may be warranted to explore this connection. Initial treatment plan includes cognitive behavioral therapy (CBT) focusing on panic management techniques, psychoeducation regarding panic disorder and potential GAD implications, and exploration of selective serotonin reuptake inhibitors (SSRIs) for symptom management. Patient education regarding panic disorder, anxiety management strategies, and the potential role of glutamic acid decarboxylase will be provided. Follow-up scheduled in two weeks to assess treatment response and determine the need for further diagnostic workup or treatment adjustments. Medical billing codes will be determined based on diagnostic assessment and treatment provided, including codes related to panic disorder, anxiety disorders, and potential GAD antibody testing. Documentation will be maintained in the electronic health record according to established clinical documentation improvement (CDI) guidelines.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.